Loading
A phase 2/3 trial of pembrolizumab in lung cancer, run by Canadian Cancer Trials Group, active but no longer recruiting.
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer is a phase 2/3, randomised interventional study registered as NCT04093167 by Canadian Cancer Trials Group, with a registry enrolment figure of 53 participants, started 2020-05-26 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pembrolizumab. Conditions listed: Lung Cancer. Primary outcome: Stage 1: Concordance rate between molecular response and radiologic response; Stage 2: Phase II Progression-Free Survival (PFS); Stage 2: Phase III Overall Survival. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed metastatic NSCLC". Sites: Canada, United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Canadian Cancer Trials Group (CCTG), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.